Skip to main content
Premium Trial:

Request an Annual Quote

Iridia: Buck Watia

Buck Watia has been appointed as VP of corporate development at DNA-based data storage firm Iridia. He joins the Carlsbad, California-based firm from Microsoft, where he was head of strategy and growth in the security, cloud, and AI business. Previously, he led business and corporate development at CyberX, which was acquired by Microsoft in 2020. Earlier, he held roles at Rapid7, ArcSight, and iDefense. Watia has a bachelor of business administration from Boise State University.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.